Rating Change
Needham reiterated its Buy rating on Cellebrite DI Ltd. (NASDAQ:CLBT) on November 12, 2026.
Needham reiterated its Buy rating on Cellebrite DI Ltd. (NASDAQ:CLBT) on November 12, 2026.

At publication ·
Cellebrite DI Ltd. (NASDAQ:CLBT) · reiterate
At a glance
Needham reiterated its Buy rating on Cellebrite DI Ltd. (NASDAQ:CLBT) on November 12, 2026.
Cellebrite DI Ltd. operates in the Technology sector. The stock currently trades at $11.67 with a market capitalization of $4.7B. The stock has declined 30.6% over the past 52 weeks.
Analyst coverage from Needham provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Cellebrite DI Ltd.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Nov 12, 2026 | Needham | Buy | N/A |
| Sep 15, 2026 | DA Davidson | Buy | N/A |
| Aug 14, 2026 | Lake Street | Buy | N/A |
| Aug 14, 2026 | JP Morgan | Overweight | N/A |
| Aug 14, 2026 | DA Davidson | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View CLBT Stock Page
A rating of Buy from Needham reflects the analyst's outlook on Cellebrite DI Ltd. (NASDAQ:CLBT). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the CLBT forecast page.
Current market data
NASDAQ · CLBT
$11.53
Up: +$0.64 · +5.88%
Live quote updated
Keep reading